Moderna Rises, Abercrombie & Finch Drops, and Brown-Forman Gains on Better Than Feared Guidance

On this episode of Stock Movers:

- Moderna (MRNA) shares rise after the company agreed to pay $950 million to settle litigation related to the delivery technology behind its Covid shot, removing a looming financial risk for the struggling vaccine maker. The company has settled all litigation worldwide with Arbutus Biopharma Corp. and Genevant Sciences GmbH over its existing and future vaccines, with no future royalties owed.

- Abercrombie & Finch (ANF) drops after the apparel retailer’s forecast for first quarter net sales growth and profits trailed the consensus estimates. Fourth quarter comparable sales performance also missed expectations, with Hollister growth failing to reach expectations. 

- Brown-Forman (BF) shares gains ahead of the bell after the alcohol beverage company reported earnings per share for the third quarter that beat the average analyst estimate. Net sales were also slightly better. Management reiterated its annual guidance, though stated that the operating environment for fiscal 2026 continues to be “challenging” and visibility is low due to “macroeconomic and geopolitical volatility.

See omnystudio.com/listener for privacy information.